期刊
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
卷 18, 期 2, 页码 99-100出版社
NATURE PORTFOLIO
DOI: 10.1038/s41575-020-00410-4
关键词
-
In 2020, significant progress was made in three major areas of pancreatic ductal adenocarcinoma (PDAC) research: risk factors, therapeutic resistance, and tumor recurrence. The pathophysiology of obesity-mediated PDAC initiation was elucidated, novel stromal mechanisms of therapeutic resistance were unveiled, and the genetic evolution of recurrent PDAC under therapeutic pressures was tracked in human samples.
Key advances An endocrine-exocrine axis involving cholecystokinin secretion by remodelled beta-cells drives obesity-mediated pancreatic ductal adenocarcinoma (PDAC) progression, and this process can be intercepted through weight loss strategies4. Novel avenues for stromal manipulation to improve PDAC therapy were identified in the form of LCCR15+ cancer-associated fibroblasts, which can be used to predict immunotherapy resistance7. Whole-exosome sequencing of primary tumour and matched autopsy samples from patients with recurrent PDAC demonstrated treatment-induced genetic bottlenecks and intermetastatic seeding leading to subclonal heterogeneity in the recurrent tumours, also identifying potentially targetable genetic signatures in recurrent disease9. In 2020, important advances were made across three major frontiers of pancreatic ductal adenocarcinoma (PDAC) research: risk factors, therapeutic resistance and tumour recurrence. Pathophysiology of obesity-mediated PDAC initiation was elucidated, novel stromal mechanisms of therapeutic resistance were unveiled and the genetic evolution of recurrent PDAC under therapeutic pressures was tracked in human samples.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据